If you don't have a login or your access has expired, you will need to purchase a subscription to gain access to this article, including all our online content.
For more information on individual annual subscriptions for full paid access and corporate subscription options please contact us.
To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.
For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk
6 October 2020 In a victory for GlaxoSmithKline, the US Court of Appeals for the Federal Circuit has revived a 2017 jury verdict ordering Teva to pay $235 million over the drug Coreg.
4 March 2021 UK innovation hub CPI has received a further £5 million investment from the UK government to support the development of new mRNA vaccines to protect against new variants of COVID-19.
6 October 2020 In a victory for GlaxoSmithKline, the US Court of Appeals for the Federal Circuit has revived a 2017 jury verdict ordering Teva to pay $235 million over the drug Coreg.
4 March 2021 UK innovation hub CPI has received a further £5 million investment from the UK government to support the development of new mRNA vaccines to protect against new variants of COVID-19.
6 October 2020 In a victory for GlaxoSmithKline, the US Court of Appeals for the Federal Circuit has revived a 2017 jury verdict ordering Teva to pay $235 million over the drug Coreg.
4 March 2021 UK innovation hub CPI has received a further £5 million investment from the UK government to support the development of new mRNA vaccines to protect against new variants of COVID-19.
